User profiles for Edoardo Micotti

Edoardo Micotti

Dept. of Neuroscience - Mario Negri Institute for Pharmacological Research
Verified email at marionegri.it
Cited by 2567

CX3CL1 is neuroprotective in permanent focal cerebral ischemia in rodents

…, G Chece, C Lauro, A Paladini, E Micotti… - Journal of …, 2011 - Soc Neuroscience
The chemokine CX3CL1 and its receptor CX3CR1 are constitutively expressed in the nervous
system. In this study, we used in vivo murine models of permanent middle cerebral artery …

One-pot synthesis and characterization of size-controlled bimagnetic FePt− Iron oxide heterodimer nanocrystals

…, A Falqui, C Giannini, E Micotti… - Journal of the …, 2008 - ACS Publications
A one-pot, two-step colloidal strategy to prepare bimagnetic hybrid nanocrystals (HNCs),
comprising size-tuned fcc FePt and inverse spinel cubic iron oxide domains epitaxially …

Targeting mannose-binding lectin confers long-lasting protection with a surprisingly wide therapeutic window in cerebral ischemia

…, S Fumagalli, R Ottria, JJ Reina, A Paladini, E Micotti… - Circulation, 2012 - Am Heart Assoc
Background— The involvement of the complement system in brain injury has been scarcely
investigated. Here, we document the pivotal role of mannose-binding lectin (MBL), one of …

Single severe traumatic brain injury produces progressive pathology with ongoing contralateral white matter damage one year after injury

F Pischiutta, E Micotti, JR Hay, I Marongiu… - Experimental …, 2018 - Elsevier
There is increasing recognition that traumatic brain injury (TBI) may initiate long-term
neurodegenerative processes, particularly chronic traumatic encephalopathy. However, insight into …

Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin–positive metastatic human melanoma xenografts

…, K Galler, P Richter, A Bassi, P Oliva, E Micotti… - Cancer research, 2012 - AACR
The selective delivery of bioactive agents to tumors reduces toxicity and enhances the
efficacy of anticancer therapies. In this study, we show that the antibody F8, which recognizes …

Multiple drug delivery hydrogel system for spinal cord injury repair strategies

…, M Peviani, S Papa, D Llupi, P Torriani, E Micotti… - Journal of controlled …, 2012 - Elsevier
The multifactorial pathological progress of spinal cord injury (SCI) is probably the main
reason behind the absence of efficient therapeutic approaches. Hence, very recent highlights …

[PDF][PDF] Bovine serum albumin‐based magnetic nanocarrier for MRI diagnosis and hyperthermic therapy: a potential theranostic approach against cancer

…, A Lascialfari, M Corti, P Marmorato, J Ponti, E Micotti… - small, 2010 - academia.edu
After the 2005 milestone in clinical application of paclitaxel–albumin nanoparticles (NPs) for
the treatment of metastatic breast cancer,[1] albumin NPs have been thoroughly …

In vivo imaging of glia activation using 1H‐magnetic resonance spectroscopy to detect putative biomarkers of tissue epileptogenicity

M Filibian, A Frasca, D Maggioni, E Micotti… - …, 2012 - Wiley Online Library
Purpose: Long‐lasting activation of glia occurs in brain during epileptogenesis, which
develops after various central nervous system (CNS) injuries. Glia is the cell source of the …

[HTML][HTML] Transgenic fatal familial insomnia mice indicate prion infectivity-independent mechanisms of pathogenesis and phenotypic expression of disease

…, A Paladini, C Balducci, E Micotti… - PLoS …, 2015 - journals.plos.org
Fatal familial insomnia (FFI) and a genetic form of Creutzfeldt-Jakob disease (CJD 178 ) are
clinically different prion disorders linked to the D178N prion protein (PrP) mutation. The …

Bevacizumab-induced inhibition of angiogenesis promotes a more homogeneous intratumoral distribution of paclitaxel, improving the antitumor response

…, R Frapolli, P Richter, A Decio, O Dirsch, E Micotti… - Molecular cancer …, 2016 - AACR
The antitumor activity of angiogenesis inhibitors is reinforced in combination with chemotherapy.
It is debated whether this potentiation is related to a better drug delivery to the tumor …